GlassScriptPhysician profile
Jin Yong Lee
NPI 1699439356
$1,169.14
in general payments reported to CMS, 2019-2025
23 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2024: $730 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $141.91 | 2024-2025 | |
| Celgene Corporation | $131.41 | 2024-2025 | Reblozyl |
| Sanofi-Aventis U.S. LLC | $124.99 | 2022 | |
| Pfizer INC. | $86.42 | 2025 | |
| Incyte Corporation | $83.30 | 2024-2025 | Pemazyre, Monjuvi, Jakafi |
| Deciphera Pharmaceuticals INC. | $67.57 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Exelixis INC. | $54.13 | 2024 | Cabometyx |
| Servier Pharmaceuticals LLC | $49.93 | 2024 | |
| Abbvie INC. | $42.27 | 2024 | |
| Jazz Pharmaceuticals INC. | $39.55 | 2024 | |
| Emd Serono, INC. | $36.09 | 2024 | |
| Gilead Sciences, INC. | $33.49 | 2024 | |
| Amgen INC. | $33.12 | 2024 | Repatha, Otezla |
| Solventum Corporation | $29.99 | 2025 | V.A.C.Ulta |
| Puma Biotechnology, INC. | $29.89 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $27.61 | 2024 | Ayvakit |
| Organon LLC | $25.00 | 2022 | |
| Aadi Bioscience, INC. | $24.99 | 2024 | Fyarro |
| Eisai INC. | $24.46 | 2024 | |
| Lucid Diagnostics INC. | $24.04 | 2022 | |
| Merck Sharp & Dohme LLC | $21.90 | 2024 | Keytruda |
| Astellas Pharma US INC | $19.82 | 2024 | Padcev |
| Astrazeneca Pharmaceuticals LP | $17.26 | 2024 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Yong Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.